Sorafenib pathways published in Pharmacogenetics and Genomics

The PharmGKB review of the Sorafenib pathways has been published in the journal Pharmacogenetics and Genomics. Sorafenib (NEXAVAR®, BAY43-9006) is an oral anti-cancer drug approved for the treatment of metastatic or advanced liver, kidney, and thyroid cancers.  Although many new targeted therapies have been tested over the past decade, sorafenib remains the standard of care for these diseases due to its modest efficacy and acceptable tolerability. In this review, we discuss the pharmacokinetic and pharmacodynamic properties of sorafenib and highlight genetic variations that may contribute to the diverse pharmacological responses to sorafenib.

Find out more...

View interactive pathways on PharmGKB:
Sorafenib Pharmacokinetics Pathway
Sorafenib Pharmacodynamics Pathway

Read our new publication:PharmGKB summary: Sorafenib PathwaysPharmacogenet Genomics. 2017 Mar 30Gong Li, Giacomini Marilyn M, Giacomini Craig, Maitland Michael L, Altman Russ B, Klein Teri E

<!-- /* Font Definitions */ @font-face {font-family:Arial; panose-1:2 11 6 4 2 2 2 2 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:-536859905 -1073711037 9 0 511 0;} @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;} @font-face {font-family:DengXian; panose-1:2 1 6 0 3 1 1 1 1 1; mso-font-charset:134; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:-1610612033 953122042 22 0 262159 0;} /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0in; margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman"; mso-fareast-font-family:DengXian; mso-fareast-theme-font:minor-fareast;} .MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:Calibri; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:DengXian; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi;} @page WordSection1 {size:8.5in 11.0in; margin:1.0in 1.0in 1.0in 1.0in; mso-header-margin:.5in; mso-footer-margin:.5in; mso-paper-source:0;} div.WordSection1 {page:WordSection1;} -->

PMID: 28362716

View all pathways on PharmGKB.

Subscribe to ClinPGx Blog

Don’t miss out on the latest issues. Sign up now to get access to the library of members-only issues.